AI assistant
Lupin Ltd Capital/Financing Update 2021
61031_rns_2021-03-10_7d963be3-c55f-4fc4-8159-6e69ea1fa83d.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
March 10, 2021
BSE Limited Department of Corporate Services,
P. J. Towers, Dalai Street, Mumbai Samachar Marg, MUMBAI - 400 001.
INational Stock Exchange of India Limited Exchange Plaza, Bandra Kuria Complex, Bandra (East), MUMBAI - 400 051.
Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Dear Sir/Madam,
Enclosed is a Press Release as regards launch of the authorized generic version of Alinia®(nitazoxanide) Tablets, 500 mg of Romark Laboratories, L.C.
This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Thanking you,
FOR LUPIN LIMITED
R. V. SATAM COMPANY SECRETARY (ACS -1 1973)
End- : a/a.
LUPIN LIMITED
Registered Office: 3"i Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel : (91-22) 6640 2323. Corporate Identity Number: L24100MH1983PLCO29442 www.lupin.com
Lupin Launches Authorized Generic Version of Alinia®
Mumbai, Baltimore, March 10, 2021: Global pharma major, Lupin Limited (Lupin), today announced the launch of the authorized generic version of Alinia® (nitazoxanide) Tablets, 500 mg of Romark Laboratories, L.C.
Nitazoxanide Tablets, 500 mg, are indicated in the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum in patients 12 years of age and older.
Nitazoxanide Tablets, 500 mg (RLD: Alinia®) had estimated annual sales of USD 56 million in the U.S. (IQVIA MAT January 2021).
About Lupin Limited
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. For the nine months ended December 31, 2020, the Company invested 9.8% of its revenues on research and development.
Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.
Please visit www.lupin.com for more information.
Follow us on Twitter: https://twitter.com/LupinGlobal | LinkedIn: https://www.linkedin.com/company/lupin Facebook: http://www.facebook.com/LupinWorld/
For further information or queries please contact –
| Shweta Munjal | Arvind Bothra | Manjira Sharma |
|---|---|---|
| Head – Corporate Communications | Head – Investor Relations/Corporate M&A | General Manager – Corporate Communications |
| Email: [email protected] | Email: [email protected] | Email: [email protected] |
*Safe Harbor Statement
Alinia® is a registered trademark of Romark Laboratories, LC.